Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells
Open Access
- 1 August 2015
- journal article
- research article
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 21 (8) , 1506-1514
Abstract
No abstract availableKeywords
Funding Information
- Italian Ministry of Health
- Italian Ministry of University and Research
- Associazione Italiana per la Ricerca sul Cancro
- European Commission
- Conquer Cancer Foundation
This publication has 62 references indexed in Scilit:
- Second haploidentical peripheral blood stem cell transplantation for treatment of acute leukemia with relapse after first allogeneic peripheral blood stem cell transplantationBone Marrow Transplantation, 2015
- Haploidentical BMT Using Fully Myeloablative Conditioning, T Cell Replete Bone Marrow Grafts, and Post-Transplant Cyclophosphamide (PT/Cy) Has Limited Toxicity and Promising Efficacy in Largest Reported Experience with High Risk Hematologic MalignanciesTransplantation and Cellular Therapy, 2015
- Peripheral Blood Hematopoietic Stem Cells for Transplantation of Hematological Diseases from Related, Haploidentical Donors after Reduced-Intensity ConditioningTransplantation and Cellular Therapy, 2014
- Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosisJournal of Hepatology, 2011
- Hematopoietic Stem-Cell TransplantationNew England Journal of Medicine, 2006
- Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic TransplantsScience, 2002
- Treatment of High-Risk Acute Leukemia with T-Cell–Depleted Stem Cells from Related Donors with One Fully Mismatched HLA HaplotypeNew England Journal of Medicine, 1998
- Cyclophosphamide-Induced Immunological Tolerance: an OverviewImmunobiology, 1996
- Marrow Transplantation from Related Donors Other Than HLA-Identical SiblingsNew England Journal of Medicine, 1985
- CLINICAL MANIFESTATIONS OF GRAFT-VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONOR,STransplantation, 1974